首页> 外文期刊>Surgical infections >Ertapenem Monotherapy versus Gentamicin Plus Metronidazole for Perforated Appendicitis in Pediatric Patients
【24h】

Ertapenem Monotherapy versus Gentamicin Plus Metronidazole for Perforated Appendicitis in Pediatric Patients

机译:厄他培南单药联合庆大霉素加甲硝唑治疗小儿穿孔性阑尾炎

获取原文
获取原文并翻译 | 示例
           

摘要

Background: This study evaluated the efficacy and safety of ertapenem versus a combination of gentamicin plus metronidazole in pediatric patients with diffuse peritonitis attributable to perforated appendicitis.Methods: From January 2017 to January 2019, 80 pediatric patients with a median age of 13 years who underwent laparoscopic appendectomy because of perforated appendicitis with diffuse peritonitis were enrolled. The patients were randomly assigned to two groups of 40 patients each to receive ertapenem or combination therapy. The groups were compared regarding demographic/clinical data and outcomes of treatment. The main outcome measures were duration of hospitalization, time to achieving an afebrile state, post-operative complications, antibiotic treatment failure, and time to the start of enteral feeding.Results: The median length of the hospital stay was 5 and 8 days in the ertapenem and combination therapy groups, respectively (p < 0.0001). Patients in the ertapenem group took two days less to become afebrile (p < 0.0001). No post-operative complications were recorded in the ertapenem group, whereas in the combination therapy group, three complications were noted, but this difference was not significant (p = 0.2392). Furthermore, all patients in the ertapenem group responded to therapy, whereas in the combination therapy group, two antibiotic treatment failures were recorded, a diffrence that again was not significant (p = 0.4739). There was no difference in the time to the start of enteral feeding in the two groups.Conclusion: Both ertapenem and gentamicin plus metronidazole are safe and effective therapeutic options for the treatment of diffuse peritonitis in pediatric patients. Treatment with ertapenem results in lower complication rates, a shorter time to an afebrile state, and a shorter hospital stay.
机译:背景:本研究评估了厄他培南与庆大霉素联合甲硝唑联用治疗小儿穿孔性阑尾炎引起的弥漫性腹膜炎的疗效和安全性。方法:自2017年1月至2019年1月,接受80例中位年龄为13岁的小儿患者腹腔镜阑尾切除术因穿孔阑尾炎合并弥漫性腹膜炎而入选。将患者随机分为两组,每组40名患者接受厄他培南或联合治疗。比较各组的人口统计学/临床数据和治疗结果。主要的结局指标包括住院时间,达到发热状态的时间,术后并发症,抗生素治疗失败以及开始肠内喂养的时间。结果:该院住院时间的中位数为5天和8天。厄他培南组和联合治疗组(p <0.0001)。厄他培南组的患者少发热两天(p <0.0001)。厄他培南组未发现术后并发症,而联合治疗组中发现了三种并发症,但差异无统计学意义(p = 0.2392)。此外,厄他培南组的所有患者均对治疗有反应,而在联合治疗组中,记录了两次抗生素治疗失败,差异同样不显着(p = 0.4739)。两组开始肠内喂养的时间没有差异。结论:厄他培南和庆大霉素加甲硝唑都是治疗小儿弥漫性腹膜炎的安全有效的治疗选择。厄他培南治疗可降低并发症发生率,缩短发烧时间,并缩短住院时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号